Nova Biomedical’s Post

We identify three risk factors at admission for dysglycaemia during (the rest of) hospitalisation: 1️⃣ High haemoglobin A1c, 2️⃣ insulin treatment before admission, and 3️⃣ many comorbidities Early identification of patients at risk of in-hospital dysglycemia could initiate interventions and improve patient outcomes. Find our newest article "Risk factors at admission of in-hospital dysglycemia, mortality, and readmissions in patients with type 2 diabetes and pneumonia" open access at: https://lnkd.in/drPjqgtJ Peter Lommer Kristensen, Katrine Bagge Hansen, Carina Klarskov, Ulrik Pedersen-Bjergaard, Nordsjællands Hospital, Herlev og Gentofte Hospital

RA BIOBADASER registry study of 1128 patients going on ts/bDMARD found 107 (9.3%) w/ multimorbidity (Charlson Comorbidity index ≥ 3). Multimorbid RA were older, more SJC & signif higher DAS28; ts/bDMARD retention rate equal groups https://bit.ly/3uJS7at

Machine learning analysis of retrosp EHR data (3/20-9/22) on 2+ million showed COVID (5.3%) outcomes in #IMID pts not linked to DMARD or IMID Dx; but rather to age, unvaccinated, & comorbidities (Afib, CAD, CHF, CKD, COPD, CA, liver Dz)

In this comparative effectiveness study of patients with HFrEF requiring hemodialysis, sacubitril-valsartan therapy was associated with beneficial effects in all-cause mortality and all-cause hospitalization. https://ja.ma/4fK05Tw

💊 Thousands of patients with sickle cell disease are to be offered a new “life-changing” treatment on the NHS, following the approval and roll-out of a new drug that could significantly improve their quality of life. 🗣️ "Sickle cell disease can have a huge impact on people’s lives, and this is one of the biggest breakthroughs in treatment in recent decades, so I know how much this announcement will mean for thousands of people across the country." Read more here 👇 https://lnkd.in/eX5EgU7T #HealthLeaders #Healthcare #HealthcareNews #SickleCellDisease #NHSNews

Attention ER Docs: UTIs Need a Fresh Look Did you know? ▶ UTIs = 1M+ ED visits/year ▶ Women face 30x higher risk ▶ Current treatments often miss the mark Get the latest on evidence-based guidelines, smarter antibiotic use, and new therapies for UTIs.

Machine learning analysis of retrosp EHR data (3/20-9/22) on 2+ million showed COVID (5.3%) outcomes in #IMID pts not linked to DMARD or IMID Dx; but rather to age, unvaccinated, & comorbidities (Afib, CAD, CHF, CKD, COPD, CA, liver Dz)

Growing cases of chronic kidney disease (CKD) Yet… ·        No national renal model of care ·        An under-resourced National Renal Office ·        CKD not included in structured chronic disease management programme in general practice ·        Home dialysis disincentivised ·        Major under-resourcing of donation and transplant infrastructure However, some developments... ·        Strategic review of National Renal Office has recommended increased resources ·        A HSE business plan to include CKD in chronic disease management programme will be resubmitted ·        New drug indications may hold promise for some patients ·        National Renal Office is working to enhance access to home dialysis ·        New strategy to support resourcing of organ donation and transplant services will be presented to HSE management in early 2024 https://lnkd.in/emtaXfSc

https://bit.ly/3JDQAq9 SGLT2-Inhibitors have now completely dominated the arena of kidney disease management. In Pakistan alone, I have more than 300 patients who are using one of these drugs, showing significant improvement in their proteinuria. Most important, I haven't had a single patient with any significant side effect. All in all, a great feat. In a part of this aricle, I have chronicled the rise of SGLT2-Inhbitors along with other kidney-protective drugs. #ckd #kidneydisease #kidneyhealth #diabetes #health #protein

In July 2019, Darren Ali was rushed to St. Paul's Hospital and diagnosed with the widow maker – the often-fatal type of heart attack. The cause was elevated levels of lipoprotein (a), or Lp (a), a condition that is almost entirely genetic where small, sticky particle that carries fats like cholesterol through the bloodstream. About 20% of Canadians have high levels of Lp(a), but most people don’t know it. Physicians and researchers at the St. Paul’s Hospital Healthy Heart Program are forming a registry to help identify more patients like Ali with elevated Lp(a), learn more about it, and connect patients to the right treatments. The database will be the first in the country for this specific disorder and will launch in April at St. Paul’s and Vancouver General Hospital, with plans to expand to Quebec and Ontario in the first year as well as other sites in the province. Learn more at: https://lnkd.in/gfsXDDEk #KnowLpa